January 18, 2012 -- Novartis received SFDA approval to sell Lucentis in China. Lucentis is a treatment for wet (neovascular) age-related macular degeneration (AMD), which causes blindness and vision loss, usually in people over 50. The company also announced the China launch of Galvus, an oral diabetes treatment. Galvus is a dipeptidyl peptidase IV (DPP-IV) inhibitor indicated for people with diabetes 2. More details....
Stock Symbol: (NYSE: NVS)
